Ardelyx, Inc.
HealthcareNASDAQ:ARDX · NASDAQ Global Market
-$0.10 today
Vol 2.62M · Avg 3.55M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-36.9%
avg -63.2%
ROIC
-9.9%
avg -43.1%
ROA
-12.3%
avg -39.7%
Analysis
ROIC is currently the strongest return metric at -9.9% versus its period average of -43.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael G. Raab | President, Chief Executive Officer & Director | $1.43M | — | 61 | $1.76M | 0.71% |
Laura A. Williams | Chief Patient Officer & Interim Chief Medical Officer | $739,126.00 | — | 63 | $434,579.00 | 0.18% |
Elizabeth A. Grammer | General Counsel | $724,423.00 | — | 62 | $299,895.00 | 0.12% |
Rajani Dinavahi | Chief Medical Officer | $664,810.00 | — | — | $201,000.00 | 0.08% |
Mike Kelliher | Chief Business Officer | $622,498.00 | — | 49 | $361,766.00 | 0.15% |
John Bishop | Chief Technical & Quality Officer | $599,510.00 | — | 64 | $336,845.00 | 0.14% |
Sue Hohenleitner | Chief Financial Officer | $507,345.00 | — | 55 | $229,078.00 | 0.09% |
Eric Duane Foster | Chief Commercial Officer | — | — | 51 | $422,804.00 | 0.17% |
Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
Felecia W. Ettenberg | Chief Legal Officer | — | — | 55 | $237,000.00 | 0.10% |
James Brady | Chief Human Resources Officer | — | — | 55 | $149,836.00 | 0.06% |
Joseph Reilly | Senior Vice President of Finance & Principal Accounting Officer | — | — | 52 | $149,836.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$2.67M
Sells
62
$3.88M
Net Sentiment
$1.20M
Net selling
Most Active
RAAB MICHAEL
15 transactions
1–10 of 64
Analysis
Insiders reported 2 buys worth $2.67M and 62 sells worth $3.88M over the last 12 months. That adds up to net selling of $1.20M. RAAB MICHAEL was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -6.0% | +33.7% (14yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -6.0% over three years. Forward estimates point to Revenue at +33.7% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.02B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.86B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.83B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Upstream Bio, Inc.
UPB
$331.96M
Who manages ARDX?
Ardelyx, Inc. (ARDX) lists 12 active executives. The top listed executive is Elizabeth A. Grammer, General Counsel.
Are ARDX insiders buying or selling?
Recent insider activity shows net buying of $25.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.